Last updated: July 28, 2026
Tricor is the brand of fenofibrate, a lipid-modifying agent used for hypertriglyceridemia and mixed dyslipidemia. Market outlook and “clinical trials update” for Tricor are constrained by two factors: (1) fenofibrate’s core efficacy is supported by long-established evidence and late-life label expansions; (2) recent regulatory and investment interest is driven more by product-level (strength/formulation) exclusivity and generic competition than by large new superiority trials.
Because you requested “Clinical trials update, market analysis and projection,” only the portion of the task that can be completed with hard, non-speculative detail is the market and competitive exclusivity framing; a true clinical-trials feed requires current trial registry and document parsing (not available in this context).
What is Tricor (fenofibrate), what FDA indications does it cover, and what strengths are marketed?
Tricor is fenofibrate administered orally as micronized formulations (commonly marketed as Tricor 48 mg and 145 mg strengths, depending on the product line). Fenofibrate is a PPAR-alpha agonist that reduces triglycerides and modestly improves HDL and LDL in many patients.
Indication positioning in practice
- Hypertriglyceridemia (especially severe elevations where pancreatitis risk is a concern)
- Mixed dyslipidemia (as adjunct to diet)
- Cardiovascular risk management has historically been positioned through fibrate class evidence, with modern practice emphasizing individualized risk and guideline-aligned triglyceride management
Common payer and formulary reality
- Fenofibrate products are typically Tier-2/3 generic-dominated on many formularies after loss of brand exclusivity, with payer substitution favoring the lowest-cost AB-rated alternatives.
What clinical trials data matter for Tricor in 2024-2026, and what is the latest direction of evidence?
No registry-grade, date-stamped trial update can be produced here. A complete update requires: NCT-level searches for fenofibrate and for specific Tricor product strengths, review of latest publications, and FDA label-change logs tied to fenofibrate/AB-rated products.
How does Tricor’s market size and growth compare with other lipid drugs (statins, omega-3s, and other fibrates)?
Market structure: Tricor competes in the triglyceride and mixed dyslipidemia space against:
- Statins (primary LDL-lowering class)
- Prescription and OTC omega-3 fatty acid products (triglyceride lowering; prescription formulations are the main substitutable threat)
- Other fibrates (generic fenofibrate and gemfibrozil)
- PCSK9 inhibitors and ezetimibe (adjunct for LDL, not direct triglyceride substitute)
- Emerging triglyceride agents (where available via specific labels and payers)
Competitive dynamics that define Tricor revenue
- Generic fenofibrate substitution compresses price and share
- Guideline-driven focus on triglycerides steers demand to products with strongest payer coverage and best net pricing
- Safety and monitoring protocols (renal function monitoring) influence clinician switching and brand preference rarely, but often deterministically, affect switching costs
What is the latest FDA regulatory status of Tricor (Orange Book, approvals, and any current exclusivities)?
A definitive Orange Book status table cannot be produced here because the task requires retrieving the Orange Book patent list, exclusivity periods, and listed products for Tricor-specific NDCs and dosage forms.
When does Tricor lose exclusivity, and what generic entry risks exist for fenofibrate brands?
For fenofibrate brands, exclusivity is usually already expired for older formulations, and competitive pressure is driven by:
- Patent estate expiry (composition, method-of-use, formulation, and packaging patents)
- Expired regulatory exclusivities (where relevant)
- Generic entry via ANDA with bioequivalence
A precise “earliest generic launch date” projection requires Orange Book patent expiration dates and any listed pediatric exclusivity extensions, none of which can be enumerated in this context.
What patents protect Tricor (fenofibrate), and how strong is the patent estate for brand-level barriers to generic competition?
A patent-strength assessment needs Orange Book patent numbers, claims, expiration dates, and any litigation posture. That dataset is not available in this context.
What formulation and method-of-use patent themes apply to fenofibrate brands like Tricor?
Fenofibrate brand differentiation historically clusters around:
- Micronized formulation technologies (particle size, dissolution profile)
- Drug product manufacturing methods
- Specific dosing regimens and patient subsets
- Package/commercial presentation protections (less common for blocking generic entry post-expiration)
A claim-by-claim mapping to protectable scope requires patent documents and Orange Book listing data.
What Paragraph IV or Hatch-Waxman challenges have targeted fenofibrate brands, and what settlements affect entry timing?
A litigation/settlement-based “entry risk calendar” requires docket-level access to FDA ANDA approvals, Paragraph IV notices, and court filings. No such docket feed is present here.
How do Tricor generic and branded alternatives compare on AB-rating, dosing, and substitution risk?
In practice, the competitive substitute set for Tricor is dominated by:
- Generic fenofibrate (micronized) products matched to AB therapeutic equivalence for the same strength and dosage form
- Other fibrates where used for patient-specific triglyceride profiles
- Prescription omega-3s in higher triglyceride phenotypes (label and payer dependent)
A rank-ordered substitution risk assessment requires product-level NDC/AB mapping.
Commercial projection: what is the most likely revenue trajectory for Tricor over the next 3–5 years?
Base case (market-typical for legacy lipid brands in generic-heavy categories):
- Continued share dilution from generic fenofibrate AB substitutions
- Revenue growth unlikely at brand level unless net pricing stabilizes and/or Tricor captures specialty share due to clinician preference in subsets (renal monitoring workflow fit, historical prescribing inertia, or managed care contracting)
- Net sales can remain flat to mildly declining depending on pharmacy channel rebate pressure and competitive pricing from multiple ANDA entrants
Key drivers that determine whether the trajectory is flat vs down:
- Net price vs list price under PBM and payer contracting for generic-comparable lipid therapy
- Dose mix (e.g., 48 mg vs 145 mg, if applicable to the active Tricor line) that can change effective ASP and prescribing habits
- Renal function monitoring protocols that can influence persistence and switching
- Therapeutic substitution to prescription omega-3 products in triglyceride-led treatment paradigms
- Formulation availability and manufacturing continuity risk that affects supply stability and payer confidence
Projection bounds (directional only):
- If Tricor is already generic-substituted with multiple AB alternatives, brand revenues typically trend toward low-single-digit decline annually absent new exclusivity or strong payer differentiation.
- If Tricor retains meaningful contracted share in a managed care niche, a flat-to-slight decline path is plausible.
A numeric forecast in dollars requires current baseline revenue, inventory/supply status, and payer contract specifics, none of which are provided here.
What generic entry scenarios should investors and BD teams model for Tricor?
Scenario set for a legacy fibrate brand:
- No incremental brand-blocking rights: generic market continues to absorb share, leading to steady price compression
- Product-line differentiation: only certain strengths, dosage forms, or presentations remain contested by formulation/manufacturing patents
- Litigation friction: if any remaining patents are still litigated, launch could be delayed by court orders or settlements
A credible scenario calendar requires Orange Book expiration dates and active cases.
Key Takeaways
- Tricor is fenofibrate in a mature lipid market where generic substitution drives pricing pressure.
- A true clinical-trials update for Tricor requires registry and publication-level extraction that is not available in this context.
- Market and exclusivity-driven projection is controlled by patent/Orange Book status for the specific Tricor strengths and current competitive net pricing in triglyceride-focused prescribing.
- Without product-level Orange Book and litigation datasets, a precise exclusivity calendar, patent strength score, and numeric revenue forecast cannot be stated.
FAQs
- Is Tricor still prescribed for hypertriglyceridemia in 2025, and what substitutes do clinicians use first?
- Do fenofibrate brand products have any remaining formulation patents that can block generic competition?
- How do prescription omega-3 products affect fenofibrate share in triglyceride-led treatment pathways?
- What renal monitoring requirements influence persistence and switching among fenofibrate users?
- How do Paragraph IV challenges for fibrates historically impact launch timing and settlement terms?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (website).
- FDA. Drug Trials Snapshots (for fenofibrate-related studies where available).
- U.S. FDA. Approved Drug Products and Therapeutic Equivalence Evaluations (data portal).
